🇺🇸

US SEC Filing Intelligence

· daily

Orphan Drug Approvals — July 24, 2026

The July 24, 2026 orphan drug approval stream contained a single label expansion for SIROLIMUS (SCOMARA) by AFT PHARMACEUTICALS LTD, classified as a fallback approval with a moderately bullish signal. There were no NMEs or biosimilars approved, limiting the period's investment impact to a narrow, sponsor-specific event. The highest-conviction signal is the label expansion for SIROLIMUS, which may broaden its commercial use in a rare disease setting, though peak sales and exclusivity details remain undisclosed. Key risks include the absence of pricing power data and the lack of clarity on market positioning, which tempers the bullish thesis for AFT PHARMACEUTICALS LTD.

1 total filings
· daily

New Drug Approvals (Original) — July 24, 2026

The July 24, 2026 FDA approval digest is dominated by 10 generic/biosimilar approvals, with zero NMEs, biosimilars, or label expansions formally classified, though two approvals (SIROLIMUS and EDARAVONE) carry bullish label expansion signals. The period is characterized by high-volume generic entries from sponsors like AUROBINDO PHARMA LTD, TEVA PHARMS USA, and ZYDUS PHARMS, indicating a wave of off-patent competition across dermatology, CNS, and metabolic therapeutic areas. The highest-conviction signal is the label expansion for EDARAVONE by AZURITY PHARMACEUTICALS INC, which may broaden its addressable market in neurology, though commercial details remain undisclosed. Key risk is the lack of NME approvals, signaling a dry pipeline for novel therapies and potential investor rotation toward later-stage generic players.

10 total filings
· daily

Federal Construction & Infrastructure Contracts — July 24, 2026

This digest covers a single $130.8M civilian contract awarded to PTSI MANAGED SERVICES INC by NASA for facility design and construction at Goddard Space Flight Center, with zero defense-related exposure. The contract is substantially complete (78% paid) and was awarded under full-and-open competition on a firm-fixed-price basis, signaling stable but non-exclusive positioning in NASA infrastructure. The highest-conviction signal is neutral: the contract demonstrates successful execution over a six-year period, but the lack of follow-on awards or set-aside protections raises concentration risk for PTSI. Key watch items include PTSI's ability to win new NASA GSFC contracts post-2023 and the absence of any defense diversification in this stream.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — July 24, 2026

This digest covers a single, high-value civilian contract awarded to Leidos Holdings, Inc. via its subsidiary Leidos Biomedical Research Inc. The Department of Health and Human Services (HHS), specifically the NIH National Cancer Institute, obligated $173.3 million for Phase 1 and Phase 2 vaccine clinical trials. The contract is a cost-plus-fixed-fee delivery order with a six-year performance period (through May 2029) and $36.8 million already funded, providing Leidos with stable, low-risk revenue visibility. The highest-conviction signal is the low pricing risk and long duration, though the full $173.3 million realization depends on future funding obligations. There are no defense-related contracts in this period.

1 total filings
· daily

New Federal Contractors — July 24, 2026

This digest covers $541.8 million in new federal contracts awarded across four civilian agencies—HHS, NASA, FAA—with zero defense-related obligations, underscoring a pure civilian-sector procurement theme. The highest-conviction signal is Leidos Biomedical Research’s $173.3 million NIH cost-plus contract for vaccine trials, offering stable, long-term revenue with low profit risk. A key risk is the concentration of awards to non-defense agencies, which may face higher budget uncertainty under a continuing resolution compared to DOD funding. Investors should watch for follow-on obligations under Leidos’ NIH delivery order and potential re-competes for NASA Goddard facility work by PTSI Managed Services.

4 total filings
· daily

Significant Contract Modifications ($10M+) — July 24, 2026

This digest covers $541.8 million in civilian-only contract obligations from July 24, 2026, with zero defense-related awards, underscoring a pure civilian agency spending snapshot. The dominant theme is stable, long-duration health and infrastructure R&D, led by Leidos Biomedical Research's $173.3 million NIH vaccine trial contract—the highest-conviction bullish signal due to its cost-plus pricing and six-year revenue visibility. However, three of four contracts are neutral, with two (PTSI Managed Services at NASA, Raytheon at FAA) nearing completion or representing immaterial revenue for large-cap RTX. Key risk: the $130.8 million PTSI NASA contract is fully executed, creating a revenue gap for that contractor absent follow-on awards.

4 total filings
· daily

Contract Deobligations Alert — July 24, 2026

This digest covers $541.8 million in total obligations across four civilian agency contracts, with zero defense-related awards. The dominant theme is stable, long-duration civilian infrastructure and health R&D spending, led by a $173.3 million Leidos Biomedical Research NIH vaccine trial contract (bullish, cost-plus, low risk) and a $130.8 million PTSI Managed Services NASA facility contract (neutral, now complete). The highest-conviction signal is Leidos' competitive win in full-and-open competition for a six-year NIH delivery order, providing steady annual revenue of ~$28.9 million. A key risk is the $124.6 million Frequentis USA FAA contract, which is time-and-materials with limited margin upside and foreign ownership exposure. No bearish signals were identified, but three of four contracts are neutral, reflecting limited growth catalysts and no defense-sector tailwinds.

4 total filings
· daily

Contract Option Exercises — July 24, 2026

This digest covers four contract option exercises totaling $541.8 million, all from civilian agencies with zero defense exposure, highlighting a pronounced shift toward non-DOD spending. The dominant theme is federal health and infrastructure investment, led by a $173.3 million Leidos Biomedical Research award from NIH for vaccine clinical trials—the highest-conviction bullish signal. However, three of the four contracts are neutral, with two nearing completion (PTSI Managed Services at NASA, Raytheon at FAA) and one (Frequentis USA at FAA) showing high funding certainty but limited margin upside. Key risks include contract concentration (PTSI's near-complete NASA award) and the absence of defense contracts, which may signal a temporary lull in DOD option exercises.

4 total filings
· daily

Federal Professional Services Contracts — July 24, 2026

This single-contract digest covers a $113.2 million civilian award from the Department of Transportation (FAA) to Raytheon Company (RTX Corp) for engineering services on aircraft ground handling equipment. With zero defense-related contracts, the period is entirely civilian-focused, dominated by a sole-source, cost-plus-fixed-fee delivery order under the FAA's STARS program. The highest-conviction signal is neutral: the award confirms Raytheon's entrenched incumbent position but offers limited margin upside and immaterial revenue (~$28M annually) relative to RTX's $69B+ top line. Key risk is the lack of competitive pressure signaling potential protest vulnerability, though the sole-source nature mitigates this.

1 total filings
· daily

All HHS Contracts — July 24, 2026

This digest covers a single, high-value civilian contract from the Department of Health and Human Services (HHS) totaling $173.3 million, with no defense-related exposure. The dominant theme is NIH’s sustained investment in next-generation vaccine clinical trials, with Leidos Biomedical Research Inc. winning a six-year cost-plus-fixed-fee delivery order that provides long-term revenue visibility and low execution risk. The highest-conviction signal is the stable, cost-plus pricing structure that minimizes profit volatility for Leidos. A key watch item is the $36.8 million already funded versus the total ceiling, meaning future obligations must be monitored to confirm full contract realization.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 24, 2026

The July 24, 2026 Mega Contracts Monitor captures $541.8 million in total obligations, with zero defense-related awards—a striking civilian-only profile dominated by health, space, and transportation infrastructure. The highest-conviction signal is Leidos' $173.3 million NIH vaccine trial contract, a cost-plus, long-duration win that provides stable, low-risk revenue visibility through 2029. However, three of four contracts are neutral-rated, reflecting mature, fully competed or sole-source awards with limited growth catalysts. Key risks include the expiration of PTSI's $130.8 million NASA facility contract (now 78% paid) and potential regulatory scrutiny of Frequentis USA's foreign ownership on FAA telecom work. Investors should watch for follow-on awards at NASA Goddard and FAA budget allocations for air traffic modernization.

4 total filings
· daily

High-Value Federal Grants ($5M+) — July 24, 2026

This digest covers $541.8 million in civilian agency contracts, with zero defense exposure, highlighting a dominant theme of stable, long-duration federal health and infrastructure spending. The highest-conviction signal is Leidos Biomedical Research's $173.3 million NIH delivery order for vaccine trials, offering low-risk, cost-plus revenue through 2029. A key risk is the concentration of awards to non-defense agencies (HHS, NASA, DOT), which limits exposure to higher-growth defense priorities but provides insulation from Continuing Resolution volatility. Investors should watch for follow-on funding obligations under Leidos' contract and any re-compete activity for PTSI's completed NASA facility contract.

4 total filings
· daily

General Federal Contracts — July 24, 2026

This digest covers $541.8 million in federal contracts awarded on a single day (July 24, 2026), all from civilian agencies with zero defense exposure. The dominant theme is health and infrastructure R&D, led by Leidos Biomedical Research's $173.3 million NIH vaccine trial contract—the highest-conviction signal due to its cost-plus pricing and long duration through 2029. The FAA accounts for two contracts totaling $237.7 million (Frequentis USA and Raytheon), signaling stable air traffic modernization spending. A key risk is that two of the four contracts (PTSI Managed Services at NASA and Raytheon at FAA) are either completed or near-completion, offering no forward revenue visibility. Investors should watch for follow-on awards at NASA Goddard and FAA STARS program extensions to sustain these revenue streams.

4 total filings
· daily

All NASA Contracts — July 24, 2026

This digest covers a single, large NASA contract awarded to PTSI MANAGED SERVICES INC worth $130.8M for facility construction at Goddard Space Flight Center. The contract is entirely civilian (0% defense-related) and is substantially complete, with 78% of funds outlayed. The neutral signal reflects a stable, non-exclusive infrastructure win that is now largely executed, offering limited forward-looking investment insight. The key risk is the lack of follow-on awards or trend data, making PTSI's future revenue visibility low for this specific contract.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — July 24, 2026

The three filings present a bifurcated picture within the S&P 500 Technology sector. Texas Instruments (TXN) delivered a standout quarter with robust 22.8% YoY revenue growth and a 52.9% surge in net income, driven by its Analog segment and bolstered by CHIPS Act benefits, signaling strong cyclical recovery and operational leverage. In stark contrast, CrowdStrike (CRWD) shows a significant bearish signal from its CEO, who executed a series of stock sales totaling over $1.3M, which, while under a 10b5-1 plan, represents a material reduction in insider holdings. Palantir (PLTR) reported a neutral insider transaction with a stock appreciation rights award, offering no clear directional signal. The key portfolio-level theme is the divergence between established hardware/semiconductor companies executing on strong fundamentals and high-growth software/cybersecurity firms where insider sentiment is turning cautious. The most critical development is the combination of TXN's strong operating performance and its strategic capital allocation, which positions it favorably against peers, while CRWD's insider selling warrants close monitoring for potential further weakness in the cybersecurity sub-sector.

2 high priority 1 medium 3 total filings
· daily

Nasdaq 100 Stocks SEC Filings — July 24, 2026

The NASDAQ-100 digest reveals a stark semiconductor sector divergence: Intel's massive $11.0B net loss (vs. $2.9B loss a year ago) masks a 25% revenue surge and a 1,290 bps gross margin improvement to 40.4%, but non-operating charges (a $13.6B mark-to-market loss on Escrowed Shares) obliterated the bottom line. In contrast, Texas Instruments delivered a textbook recovery with 22.8% YoY revenue growth and 52.9% net income expansion, driven by Analog (+26.4% YoY) and a 55.9% surge in H1 operating cash flow. Palantir's insider equity award (17,124 SARs to a key executive) signals continued retention and alignment, while Lite Strategy's routine investor presentation filing carries no material financial insight. The overarching theme is a 'two-speed' semiconductor recovery: TI exemplifies operational discipline and capital efficiency (inventories down 4.1% H1), while Intel's turnaround narrative is clouded by massive financial engineering charges and Foundry losses ($2.1B operating loss). Portfolio-level patterns show robust demand in computing and AI (Intel's CCG/DCAI generating $4.8B operating income) and Analog strength (TI's Analog revenue up 26.4% YoY), but capital allocation diverges sharply—Intel's equity base eroded by $23.3B (from $126.4B to $103.1B) while TI's cash flow strength supports sustained investment. The key market implication: investors should favor semiconductor companies with clean balance sheets and operational leverage (TI) over those with restructuring overhangs and non-operating volatility (Intel), despite top-line growth at both.

2 high priority 2 medium 4 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — July 24, 2026

The 50 filings reveal a predominantly passive investment landscape with several notable activist positions and insider moves. Key themes include significant insider buying at CytoMed Therapeutics and Nex Neo Tech, a large passive stake by City of London Investment Management across multiple closed-end funds, and a bankruptcy emergence at Office Properties Income Trust with activist involvement. Period-over-period comparisons show modest share count changes and stable ownership percentages for most filers. The most actionable signals come from insider purchases, warrant vesting events, and lock-up expirations that could drive future price action.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — July 24, 2026

The 14 filings from the S&P 500 Financials sector reveal a mixed picture for Q2 2026, with strong revenue and earnings growth at American Express (AXP) contrasting with a core revenue decline at CME Group and a wave of insider selling at Travelers (TRV) and US Bancorp (USB). Capital returns remain robust, highlighted by Bank of America's (BAC) 14% dividend increase and CME's aggressive $3.2B in dividends and $1.2B in buybacks during H1 2026. However, expense growth is a key theme, with AXP's costs rising 12% YoY, outpacing its 10% revenue growth. Insider selling is concentrated among senior executives at TRV and USB, with three separate TRV filings showing sales totaling over $3.5M, signaling potential caution at current valuations. The passive stake increases by City of London Investment Management in two Morgan Stanley closed-end funds suggest a stable, value-oriented view on those specific vehicles. The debt issuance by Travelers ($750M in 4.950% Senior Notes due 2031) indicates a strategic move to lock in financing, likely for general corporate purposes or to refinance existing debt.

9 high priority 5 medium 14 total filings
· daily

S&P 500 Energy Sector SEC Filings — July 24, 2026

The S&P 500 Energy sector is exhibiting a clear divergence between top-line growth and bottom-line profitability, as highlighted by Q2 2026 filings from SLB, Halliburton, and Kinder Morgan. While all three majors reported year-over-year revenue increases, driven by strong service demand and higher commodity sales, profitability trends are mixed. SLB's earnings fell sharply, with GAAP EPS down 30% YoY, signaling margin compression from acquisition costs and regional disruptions, while Halliburton showed a 13% YoY net income increase, boosted by a one-time impairment credit. Kinder Morgan stands out as the strongest performer, with net income surging 21% YoY on robust revenue growth of 10.8%, though rising operating expenses and a 26% increase in capital expenditures warrant monitoring. A notable sector-wide theme is the pivot toward shareholder returns, with SLB aggressively repurchasing shares ($648M in Q2) and Kinder Morgan increasing dividends, even as both companies pursue capital-intensive acquisitions and digital transformation projects. A minor insider buy in Texas Pacific Land provides a faintly bullish signal for the midstream space, but the overall picture is one of an industry navigating cost inflation and geopolitical headwinds while rewarding investors through capital allocation. The key takeaway is that operational efficiency and cost control are becoming the primary differentiators for energy companies in this cycle, with Kinder Morgan currently leading on this metric.

3 high priority 1 medium 4 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — July 24, 2026

The three filings from the S&P 500 Consumer Staples sector reveal a mixed picture for the period ending July 24, 2026. Philip Morris International (PMI) reported strong top-line growth of 10.4% YoY in Q2 2026, driven by smoke-free products, but net earnings fell 7.3% due to a $511M impairment, creating a divergence between operational strength and bottom-line pressure. The Estée Lauder Companies announced a board retirement, a non-financial event with low materiality, while Clorox disclosed a routine insider tax-withholding transaction, indicating no significant management conviction shifts. Key period-over-period trends show PMI's operating income surging 22% YoY, signaling robust operational efficiency, but net income declines highlight risk from equity investments. The sector theme centers on the trade-off between revenue growth and earnings quality, with PMI's smoke-free pivot as a key growth driver. No forward-looking guidance or capital allocation changes were noted, limiting catalyst visibility. Overall, the digest points to selective opportunities in companies with strong operational momentum, while flagging risks from non-operating charges and insider transactions that lack conviction signals.

3 high priority 3 total filings